259 related articles for article (PubMed ID: 24574743)
1. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience.
Kanizaj TF; Kunac N
World J Gastroenterol; 2014 Jan; 20(3):699-705. PubMed ID: 24574743
[TBL] [Abstract][Full Text] [Related]
2. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
3. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
4. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
5. Helicobacter pylori eradication in West Asia: a review.
Fakheri H; Bari Z; Aarabi M; Malekzadeh R
World J Gastroenterol; 2014 Aug; 20(30):10355-67. PubMed ID: 25132752
[TBL] [Abstract][Full Text] [Related]
6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
Papastergiou V; Georgopoulos SD; Karatapanis S
World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
9. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.
Molina-Infante J; Gisbert JP
World J Gastroenterol; 2014 Aug; 20(30):10338-47. PubMed ID: 25132750
[TBL] [Abstract][Full Text] [Related]
10. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
11. A new look at anti-Helicobacter pylori therapy.
Chuah SK; Tsay FW; Hsu PI; Wu DC
World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Helicobacter pylori infection: which regimen first?
Federico A; Gravina AG; Miranda A; Loguercio C; Romano M
World J Gastroenterol; 2014 Jan; 20(3):665-72. PubMed ID: 24574740
[TBL] [Abstract][Full Text] [Related]
14. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
[TBL] [Abstract][Full Text] [Related]
15. [Helicobacter pylori-associated diseases].
Gisbert JP
Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori-related diseases.
Gisbert JP
Gastroenterol Hepatol; 2016 Sep; 39 Suppl 1():36-46. PubMed ID: 27888863
[TBL] [Abstract][Full Text] [Related]
17. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Helicobacter pylori infection: Where are we now?
Liou JM; Wu MS; Lin JT
J Gastroenterol Hepatol; 2016 Dec; 31(12):1918-1926. PubMed ID: 27088632
[TBL] [Abstract][Full Text] [Related]
19. Practical Aspects in Choosing a Helicobacter pylori Therapy.
Molina-Infante J; Shiotani A
Gastroenterol Clin North Am; 2015 Sep; 44(3):519-35. PubMed ID: 26314666
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]